Promising antibody therapy may help kidney patients stay Relapse-Free longer

NCT ID NCT07233330

Not yet recruiting Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called obinutuzumab in 10 adults with a kidney condition called nephrotic syndrome that keeps coming back despite standard treatments. The goal is to see if a single course can keep patients relapse-free for at least 12 months by deeply depleting certain immune cells. Participants will be monitored for safety and how long the effect lasts.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME，IDIOPATHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic nephrotic syndrome lipoid nephrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEPHROTIC SYNDROME，IDIOPATHIC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Research Centre for Rare Diseases Aldo e Cele Daccò

Ranica, BG, 24020, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••